One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.
Coronary intervention technology is at a crossroads. The promise of drug-eluting stents has been realized, and current DES are highly deliverable, dramatically reduce in-stent restenosis compared to bare-metal stents, and the risk of stent thrombosis with DES appears to be mostly manageable.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
